Indian Pharmas Seek Probe Into Delays Of Patent-Dispute Decisions
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical industry is demanding an investigation into delays in orders of medicines that are involved in patent disputes. The Indian Pharmaceutical Alliance urged the patent office to check on "inordinate delays" in issuing final orders in cases in which its members have challenged patent grants under patent-enforcement regulations. The appeal was issued by the IPA to the controller general of patents, designs and trademarks and the chief patent-enforcement agency. It said several drug makers have taken advantage of delayed decisions, some delayed for at least six months beyond a final hearing. (Click here for more
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.